Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupropion + escitalopram
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of bupropion and escitalopram is used in the treatment of major depressive disorder (MDD), particularly for patients who have had an inadequate response to antidepressant monotherapy. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI), while escitalopram is a selective serotonin reuptake inhibitor (SSRI). Together, they target different neurotransmitter systems—bupropion increases norepinephrine and dopamine levels by inhibiting their reuptake, and escitalopram increases serotonin levels by selectively blocking its reuptake at the serotonin transporter. This combination aims to improve efficacy over monotherapy by addressing multiple neurochemical pathways involved in depression. Clinical studies suggest that this regimen can be effective and well tolerated, with higher rates of response and remission compared to SSRI monotherapy[2][4][5]. However, combining these medications may increase the risk of certain side effects such as seizures or serotonin syndrome[1][3].
- Brand names
- Wellbutrin + Lexapro
- Other names
- bupropion-SR + escitalopramWellbutrin SR + Lexapro
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on bupropion + escitalopram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupropion + escitalopram.